Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 15/20 | 0.46 |
| ▸ | VEGFA | P15692 | 6/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19870743 | 0.88 | EPAS1 (0.42) | EPAS1VEGFA | |
| SCHEMBL19858559 | 0.88 | EPAS1 (0.42) | EPAS1VEGFA | |
| SCHEMBL18067976 | 0.88 | EPAS1 (0.42) | EPAS1VEGFA | |
| SCHEMBL19858577 | 0.76 | EPAS1 (0.58) | EPAS1VEGFA | |
| SCHEMBL21362868 | 0.76 | EPAS1 (0.53) | EPAS1VEGFA | |
| SCHEMBL18049076 | 0.76 | EPAS1 (0.58) | EPAS1VEGFA | |
| SCHEMBL28637879 | 0.73 | EPAS1 (0.61) | EPAS1VEGFA | |
| SCHEMBL19870928 | 0.72 | EPAS1 (0.57) | EPAS1VEGFA | |
| SCHEMBL19870952 | 0.72 | EPAS1 (0.59) | EPAS1VEGFA | |
| SCHEMBL18688694 | 0.71 | EPAS1 (0.56) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 47/4885SLC9A1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.